12 C
Madrid
Sunday, May 9, 2021

‘Lift Embargo On COVID-19 Vaccine Raw Materials’: SII CEO Urges US Prez

Over 80,000 Fresh Infections In Maharashtra And Delhi

Must read

Raju Vernekar
Raju Vernekar
I am a mumbai based journalist having worked with many daily newspapers.

INDIA.Mumbai: Amid the reports of vaccine shortage in the country, the Pune-based “Serum Institute of India” (SII) CEO Adar Poonawalla, on Friday, urged US President Joe Biden to lift the embargo on vaccine raw material exported out of the country so that vaccine production can be ramped up. 

“Respected @POTUS, if we are to truly unite in beating this virus, on behalf of the vaccine industry outside the U.S., I humbly request you to lift the embargo of raw material exports out of the U.S. so that vaccine production can ramp up. Your administration has the details,” said Poonawalla in a tweet.

- Advertisement -

Poonawalla’s tweet came following Oxford-AstraZeneca’s legal notice to the SII, for delays in deliveries. The Serum chief had earlier admitted that SII has been facing problems in sending out the required number of batches of COVID-19 vaccines due to bureaucratic and government-related hurdles. He had also said that SII would need around Rs.3,000 crore to ramp up COVID-19 vaccine production capacity. The SII has already delivered over 100 million doses to India and exported around 60 million doses to other countries.

The CEO had earlier stated that the US has implemented the Defence Act that bans the export of raw materials leading to difficulties to several vaccine manufacturers. Poonawalla called the restriction “as good as banning vaccines”. Poonawalla, whose company is also manufacturing the “Novavax coronavirus vaccine”, said that the production of the same has been stalled because of the raw material shortage. The unavailability of the raw materials, such as the specific medium needed to grow microorganisms, would prevent Serum Institute from scaling up the production of the vaccine developed by “Novavax”. The firm had been planning to make up to 40 million shots of the vaccine monthly.

- Advertisement -

“There is a long list of raw materials which we import from the US – filters, bags, certain media solutions, etc. Developing new suppliers in the eleventh hour will take a bit of time. We will do that. We will not be dependent on the US after six months. The problem is we need it now”, Poonawalla stated.

The raw materials required by SII

The list of raw materials that SII imports from the US include the “adjuvant” and large sterile plastic bags used to grow vaccine cells. An adjuvant is a substance that is used to increase the efficacy of a vaccine and helps the immune system generate antibodies. While vaccine manufacturers can establish a fresh supply chain for raw materials like filters and sterile plastic bags, the disruption in the supply of adjuvant can hamper production for a longer period. Authorized vaccines are made with a certain adjuvant and any change in the vendor of that adjuvant would lead to fresh clinical trials and approvals.

- Advertisement -

Poonawalla said that “AstraZeneca has sent us legal notice and the Indian government is also aware of that. I cannot comment on the legal notice as it is confidential, but we are examining all avenues to amicably manage and resolve legal disputes over contractual obligations that Serum Institute is not able to fulfill due to its prioritization of Indian supplies”.

The Serum Institute is currently manufacturing the anti-coronavirus vaccine “Covishield”, developed by AstraZeneca and Oxford University. The “Covishield” is not only being used in India but also exported to several nations.

In November last year, American pharmaceutical company Pfizer Inc. cut short its vaccine production target by half, citing a shortage of raw material. Pfizer, which is producing mRNA Covid-19 vaccines, had earlier planned to roll out over 1.2 billion shots this year, but reduced the target by half due to raw material shortage in the United States and Europe.

The vaccine shortage in India 

Multiple states including Maharashtra, Punjab, Rajasthan have already written to the Centre, flagging dwindling COVID-19 vaccine stocks. Many districts in Karnataka, Odisha, and Kerala have also said that their vaccine stock is rapidly getting over.

A surge in COVID-19 cases

In the meanwhile on Friday, the daily new cases in the deadly second wave took the overall tally to 1.42 crore in the country. Maharashtra and Delhi both reported their highest single-day spike in COVID-19 cases with over 80,000 fresh infections between the two states. 

Delhi on Friday recorded 19,486 fresh Covid-19 cases and 141 deaths due to the disease. This was the fifth record daily rise in cases in the national capital in the last six days.

Maharashtra, by far the worst-hit state in the entire country, logged 63,729 fresh coronavirus cases taking the tally to 37,03,584, while 398 fatalities pushed the death toll to 59,551. The state’s earlier highest one-day case count was 63,294, recorded on April 11, followed by 61,695 on April 15. Maharashtra’s COVID-19 recovery rate stood at 81.12 percent, while the fatality rate was 1.61 percent. The Nagpur division registered 10,559 cases, while the Pune division saw 13,891 fresh infections. Mumbai recorded 8,803 new cases and 53 fatalities, taking the tally to 5,62,207 and the toll to 12,250. With 2,72,226 new tests, the number of samples tested so far in Maharashtra has gone up to 2,33,08,878.

Support our mission of Independent Journalism on Patreon!
- Advertisement -

More articles

- Advertisement -

Latest article

Support our mission of Independent Journalism on Patreon!